Kintara Therapeutics, Inc., a clinical-stage biopharmaceutical company, operates in the healthcare industry with a focus on the development and commercialization of new cancer therapies. The company's primary product, VAL-083, is a first-in-class, small-molecule, DNA-targeting chemotherapeutic that has demonstrated activity against a range of tumor types in prior human Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (NCI). VAL-083 is a DNA-targeting agent that forms inter-strand crosslinks at the N7 position of...